Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Retrieved on:
Friday, September 16, 2022
Adult, Observation, Therapy, Investor, Injection, Trial of the century, Safety, American College, Risk, University of Auckland, CRISPR, Nobel Prize, Medicine, Intellia Therapeutics, Faculty, Form 10-K, Private Securities Litigation Reform Act, ACAAI, Hereditary angioedema, Bradykinin, U.S. Securities and Exchange Commission, Patient, Clinical trial, History, Cancer, Cas9, Cell, Prekallikrein, Genetic disorder, Liver, Tissue, Degenerative disease, SC, NASDAQ, Plasma kallikrein, KLKB1, Security (finance), Pharmacokinetics, GLOBE, SEC, HAE, University of Auckland Faculty of Medical and Health Sciences, Annual report, Genome, Webcast, University, Plasma, NTLA, Aluminium, Pharmaceutical industry, Vaccine
The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.
Key Points:
- The interim data were shared today in an oral presentation at the 2022 Bradykinin Symposium held in Berlin, Germany.
- To date, all three patients in the 25 mg dose cohort have reached the end of this initial observation period.
- Treatment with a single dose of 25 mg of NTLA-2002 resulted in a mean reduction in HAE attacks of 91% throughout the 16-week observation period.
- This press release contains forward-looking statements of Intellia Therapeutics, Inc. (Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995.